Minocycline,Metronidazole — Competitive Intelligence Brief

Minocycline,Metronidazole (Minocycline,Metronidazole) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antibiotic. Area: Infectious Disease.

marketed Combination antibiotic Bacterial 30S ribosome (minocycline); microbial DNA/RNA (metronidazole) Infectious Disease Small molecule

Target snapshot

Minocycline,Metronidazole (Minocycline,Metronidazole) — Shanghai Jiao Tong University School of Medicine. This combination of minocycline (a tetracycline antibiotic) and metronidazole (a nitroimidazole antimicrobial) works synergistically to inhibit bacterial protein synthesis and DNA/RNA metabolism, respectively, providing broad-spectrum antimicrobial coverage.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Minocycline,Metronidazole TARGET	Minocycline,Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic	Bacterial 30S ribosome (minocycline); microbial DNA/RNA (metronidazole)
levofloxacin; metronidazole	levofloxacin; metronidazole	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed	Fluoroquinolone + Nitroimidazole combination antibiotic	Bacterial DNA gyrase, topoisomerase IV (levofloxacin); bacterial DNA (metronidazole)
Colistin/Polymyxin B + Tigecycline/Eravacycline	Colistin/Polymyxin B + Tigecycline/Eravacycline	National University of Singapore	marketed	Polymyxin + tetracycline combination antibiotic	Bacterial cell membrane (polymyxins) and 30S ribosome (tetracyclines)
Meropenem + Fosfomycin	Meropenem + Fosfomycin	National University of Singapore	marketed	Combination antibiotic (carbapenem + phosphonic acid antibiotic)	Penicillin-binding proteins (meropenem); MurA/UDP-N-acetylglucosamine enolpyruvyl transferase (fosfomycin)
azithromycin and cefixime	azithromycin and cefixime	Sheba Medical Center	marketed	Combination antibiotic (macrolide + third-generation cephalosporin)	Bacterial 50S ribosome (azithromycin); bacterial cell wall peptidoglycan (cefixime)
amoxicillin and metronidazole	amoxicillin and metronidazole	University of Campinas, Brazil	marketed	Combination antibiotic (beta-lactam + nitroimidazole)	Bacterial cell wall (penicillin-binding proteins) and anaerobic bacterial DNA
amoxicillin rifabutin	amoxicillin rifabutin	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic (beta-lactam + rifamycin)	Penicillin-binding proteins (amoxicillin); bacterial RNA polymerase (rifabutin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antibiotic class)

1. Aga Khan University · 1 drug in this class
2. Shanghai Jiao Tong University School of Medicine · 1 drug in this class